Tuesday, September 16, 2014

Top 5 Income Companies To Buy Right Now

This story has been updated with comments from Seagate CFO Pat O'Malley, the company's outlook and updated share price.

NEW YORK (TheStreet) - Seagate (STX) shares slid in extended trading, weighed down by the company's top and bottom-line miss in its first-quarter results.

The Cupertino, Calif.-based firm reported revenue of $3.5 billion, down from $3.7 billion in the prior year's quarter. Analysts surveyed by Thomson Reuters were looking for sales of $3.56 billion.

Excluding items, Seagate earned $1.29 a share on net income of $473 million, down from $1.45 a share on net income of $594 million in the same period last year, and just below analysts' forecast of $1.30 a share. However, Seagate CFO Pat O'Malley told TheStreet that profits were lifted in last year's quarter thanks to the lingering effects of Thailand's 2011 floods. "That was the last of the quarters where the flood impacted," he said. "There was pricing leverage because there wasn't full supply out there." On a non-GAAP basis, the company's gross margin was 28.5% during its most recent quarter, compared to 29% in the prior year's quarter. For the second quarter, Seagate predicts revenue between $3.5 billion and $3.6 billion, slightly below Wall Street's forecast of $3.64 billion. The company also expects to report a relatively flat gross margin. Seagate shares, which closed up 0.1% at $49.85 during Monday's session, tumbled 4.51% to $47.60 in extended trading. Seagate, which generated $682 million in operating cash flow during the quarter, will increase its dividend from 38 cents a share to 43 cents a share. The dividend will be payable on Nov. 26, 2013 to shareholders of record as of the close of business on Nov. 12, 2013 "While the challenges of technology transitions and macro uncertainty are driving us to manage our business conservatively, we remain focused on the fact that the demand for exabytes of storage continues to increase," said Steve Luczo, Seagate's chairman and chief executive officer, in the company's press release --Written by James Rogers in New York. Follow @jamesjrogers >Contact by Email.

Top 10 Penny Stocks To Own For 2015: Navios Maritime Partners LP (NMM)

Navios Maritime Partners L.P. (Navios Partners) is an international owner and operator of dry cargo vessels formed by Navios Holdings. Navios GP L.L.C. (the General Partner), a wholly owned subsidiary of Navios Maritime Holdings Inc. (Navios Holdings) acts as the general partner of Navios Partners and received a 2% general partner interest in Navios Partners. Navios Partners is engaged in the seaborne transportation services of a range of drybulk commodities, including iron ore, coal, grain and fertilizer, chartering its vessels under medium to long-term charters. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Orbiter, a 76,602 deadweight Panamax vessel. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Luz. In June 2012, the Company purchased the Navios Buena Ventura, a 2010 South-Korean-built Capesize vessel of 179,259 dwt from Navios Maritime Holdings Inc.

The Company is an international owner and operator of drybulk carriers formed by Navios Maritime Holdings Inc., a vertically integrated seaborne shipping company. Its vessels are chartered-out under medium to long-term time charters with an average remaining term of approximately four years to a group of counterparties, consisting of Cosco Bulk Carrier Co. Ltd., Mitsui O.S.K. Lines Ltd., Samsun Logix, STX Panocean, Sanko Steamship Co. Ltd., Daiichi Chuo Kisen Kaisha, Augustea Imprese Maritime, Rio Tinto, Constellation Energy Group and Mansel.

As of December 31, 2011, the Company�� fleet consisted of 11 Panamax vessels, six Capesize vessels and one Ultra-Handymax vessel. Its fleet of dry cargo vessels has an average age of approximately 5.6 years. Panamax vessels are flexible vessels capable of carrying a range of drybulk commodities, including iron ore, coal, grain and fertilizer. All of its vessels operate under medium to long-term time charters of three or more years at inception with counterparties. It also operates vessels in the spot market until the vessels have! been fixed under appropriate medium to long-term charters.

The Company competes with China Ocean Shipping, China Shipping Group, Mitsui O.S.K. Lines, Kawasaki Kisen, Nippon Yusen Kaisha, Cargill, Pacific Basin Shipping, Bocimar, Zodiac Maritime, Louis Dreyfus/Cetragpa, Cobelfret and Torvald Klaveness.

Advisors' Opinion:
  • [By Eric Volkman]

    As far as unitholder payouts are concerned, the seas for Navios Maritime Partners (NYSE: NMM  ) are calm and smooth. The company has declared its latest quarterly distribution, which is to be $0.4425 per unit paid on Aug. 13 to holders of record as of Aug. 8. That amount matches each of Navios' previous four disbursements, the most recent of which was paid in mid-May. Previous to that, the company handed out a quarter-cent less, at $0.44 per share.

Top 5 Income Companies To Buy Right Now: WiLan Inc (WILN)

WiLAN Inc. (WiLAN), incorporated on May 14, 1992, is a licensing company. WiLAN develops, acquires, and licenses a range of intellectual property that drives products in communications and consumer electronics markets. Through both internal research and development and acquisitions from third parties, the Company has acquired intellectual property in the form of patents and patent applications in many countries that it has licensed to more than 255 companies in telecommunications markets around the world. As of December 31, 2011, WiLAN had a portfolio of approximately 3,000 patents, including issued and pending patents and foreign equivalents. WiLAN has five directly wholly-owned subsidiaries, Wi-LAN Capital Inc. (WiLAN Capital), Wi-LAN International Inc. (WiLAN International), Wi-LAN International Hong Kong Inc. (WiLAN Hong Kong), Wi-LAN International Japan Inc. (WiLAN Japan) and Wi-LAN International Taiwan Inc. In July 2012, it acquired a global portfolio of more than 40 patents and applications from Siemens AG related to telecommunication network management and mobile multimedia. In October 2012, the Company acquired a global portfolio of more than 150 patents and patent applications from Alvarion Ltd. In June 2013, WiLan Inc acquired a portfolio of patents from Cypress Semiconductor Corporation. In November 2013, the Company acquired a portfolio of semiconductor patents from IXYS CH GmbH related to microcontroller technology.

In the Company's licensing business, the Company has signed licenses with companies that sell products utilizing technologies, including CDMA (Code Division Multiple Access-a cellular telecommunications specification); Wi-Fi (the underlying technology of wireless local area networks based on various IEEE 802.11 specifications); WiMAX (Worldwide Interoperability for Microwave Access-a standards-based broadband wireless technology that provides metropolitan area network connectivity based on IEEE 802.16 specifications); LTE (Long Term Evolution-high performance air! interface for cellular mobile communication systems designed to increase the capacity and speed of mobile telephone networks), and ADSL (Asymmetric Digital Subscriber Line-a standards-based access technology that provides broadband Internet access over twisted pair telecommunications wiring). The Company has also signed licenses with companies that sell products utilizing technologies, including DOCSIS (Data Over Cable Service Interface Specifications-a standards-based access technology that provides broadband Internet access over cable networks); Bluetooth (a wireless protocol for exchanging data over short distances between fixed and mobile devices), and V-Chip (a technology that permits the blocking of television programs at a receiver (such as a television, multi-media equipped personal computer or set-top box) by viewers based on ratings information carried on the television signal).

Advisors' Opinion:
  • [By Monica Gerson]

    Breaking news

    Wi-LAN (NASDAQ: WILN) today announced that its Board of Directors has initiated a process to explore and evaluate a broad range of strategic alternatives for the Company to enhance shareholder value. To read the full news, click here. MannKind (NASDAQ: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for AFREZZAċş (insulin human [rDNA origin]) Inhalation Powder. To read the full news, click here. lululemon athletica (NASDAQ: LULU) today announced that Tara Poseley has been appointed to its Senior Leadership Team as Chief Product Officer. To read the full news, click here. Nice Systems (NASDAQ: NICE) reported a drop in its third-quarter profit. To read the full news, click here.

    Posted-In: Bank of America FOMC US Stock FuturesNews Eurozone Futures Pre-Market Outlook Markets

  • [By Rich Duprey]

    Often accused of being a patent troll,�non-performing entity�WiLAN� (NASDAQ: WILN  ) wrangled a settlement out of Dell (NASDAQ: DELL  ) with details of the deal remaining confidential.

Top 5 Income Companies To Buy Right Now: Deutsche Bank AG (LBND)

Deutsche Bank AG is a global investment bank. The Company offers a variety of investment, financial and related products and services to private individuals, corporate entities and institutional clients around the world. The Company operates through such divisions as: Private and Business Clients, Asset and Wealth Management, Corporate Banking and Securities, Global Transaction Banking and Non-Core Operations Unit. Deutsche Bank AG is active domestically and in various countries, through the network of numerous branches. In February 2014, the Company and its related bodies corporate ceases to a share holder in the capital of the Company. Advisors' Opinion:
  • [By Donald van Deventer]

    Long-duration Treasury Exchange-Traded Funds: (TLH), , (IEF), (DTYL), (DLBL), (ILTB), (TENZ), (ITE), (TLO), (EDV), (VGIT), (VGLT), (TMF), (TYD), (LBND), (UBT), (UST), (TMV), (TYO), (DSTJ), (DSXJ), (SBND), (PST), (DTYS), (DLBS), (TBF), (TTT), (TYNS), (TYBS), (TBX).

Top 5 Income Companies To Buy Right Now: Cleveland BioLabs Inc.(CBLI)

Cleveland BioLabs, Inc., a biotechnology company, engages in the discovery, development, and commercialization of products for cancer treatment, and protection of normal tissues from radiation and other acute stresses. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines; Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation; and Curaxins, which are small molecules intended to destroy tumor cells by simultan eously targeting two regulators of apoptosis. The company has a strategic research partnership with Roswell Park Cancer Institute to develop its anticancer and radioprotectant drug candidates; a strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds; and a strategic alliance with The Cleveland Clinic Foundation (CCF). It also has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences; the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.; and CCF to evaluate its radioprotective drug candidates and their effects on intracellular and extracellular signaling pathways. The company was founded in 2003 and is headquartered in Buffalo, New York.

Advisors' Opinion:
  • [By Lisa Levin]

    Cleveland BioLabs (NASDAQ: CBLI) shares tumbled 34.67% to touch a new 52-week low of $0.74 as the company reported that BARDA has terminated negotiations related to its proposal for further development of Entolimod.

No comments:

Post a Comment